The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.
 
Wei-Chu Victoria Lai
No Relationships to Disclose
 
Daniel L. Feldman
No Relationships to Disclose
 
Darren J. Buonocore
Stock and Other Ownership Interests - Merck; Novartis
 
Edyta B. Brzostowski
No Relationships to Disclose
 
Hira Rizvi
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Joshua K. Sabari
No Relationships to Disclose
 
Michael David Offin
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca
 
Alexander E. Drilon
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Ignyta; Loxo; Pfizer; Takeda; TP Therapeutics
 
Maria E. Arcila
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Matthew David Hellmann
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Novartis
Research Funding - Bristol-Myers Squibb
 
Bob T. Li
Consulting or Advisory Role - Biosceptre International; Guardant Health; Mersana; Roche; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); GRAIL (Inst); Illumina (Inst); Roche/Genentech (Inst)